netbook
desktop
mobile
tablet-landscape
tablet
phone-landscape
phone
Research to Prevent Blindness

Statins May Treat Dry AMD

Left: before statin treatment; right: same patient, one year after statin treatment. Photo: Harvard University

 RPB-supported researchers at Massachusetts Eye and Ear/Harvard Medical School and scientists at University of Crete have conducted a phase I/II clinical trial investigating the efficacy of statins (cholesterol-lowering medications) for the treatment of patients with the dry form of age-related macular degeneration (AMD) — the leading cause of blindness in the developed world. Although effective treatments are available for the wet form of AMD, they are currently lacking for the more prevalent dry form.

The researchers found evidence that treatment with high-dose atorvastatin (80mg) is associated with regression of lipid deposits and improvement in visual acuity, without progression to advanced disease, in high-risk AMD patients.

Read the story.

Read the study.

Related News: Feature Story, Macular Degeneration, Top Story

RPB and Partners Award $1.2 Million In Grants for Novel AMD Research

Four new grantees received the Catalyst Awards for Innovative Research Approaches for AMD.

Read More

 

The Career Development Award Turns 30: Celebrating a Generation of Support for Early-Career Scientists

CDA founded 30 years ago as one of the few private sources of funding aimed specifically at early-career vision researchers.

Read More

 

Could An Eye Exam Reveal Alzheimer’s Disease?

Study from RPB-supported researchers at Duke University suggests loss of blood vessels in retina reflect changes in brain health.

Read More

 

New Findings on Blood Vessel Regulation

A study from an RPB-supported researcher at Northwestern University School of Medicine could speed up the diagnosis of retinal diseases.

Read More

 

RPB-SUPPORTED RESEARCHERS INTEGRAL TO NEI’S AUDACIOUS GOALS INITIATIVE

Vision scientists who have received RPB funding will help lead all five research teams, which will seek to accelerate development of regenerative treatments for blindness.

Read More

 

EMERGING VISION SCIENTISTS EDUCATE, THANK CONGRESS FOR RESEARCH APPROPRIATIONS

(NAEVR) held its Fourth Annual Emerging Vision Scientists (EVS) Day on Capitol Hill and twenty early-stage investigators participated.

Read More

 

Subscribe

Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.